Monoclonal Antibody Therapeutics
•152 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (152)
| Company | Market Cap | Price |
|---|---|---|
|
LLY
Eli Lilly and Company
Lilly relies on monoclonal antibody therapeutics across indications.
|
$816.66B |
$863.11
+2.20%
|
|
JNJ
Johnson & Johnson
Johnson & Johnson's portfolio includes multiple monoclonal antibody therapeutics (e.g., DARZALEX, CARVYKTI, TECVAYLI, TALVEY) across oncology and immunology.
|
$454.86B |
$188.88
-0.09%
|
|
ABBV
AbbVie Inc.
AbbVie directly commercializes monoclonal antibody therapeutics (e.g., Skyrizi) as a core immunology asset.
|
$385.15B |
$218.07
-4.44%
|
|
AZN
AstraZeneca PLC
AZN develops monoclonal antibody therapeutics across oncology and immunology.
|
$255.44B |
$82.39
+0.06%
|
|
MRK
Merck & Co., Inc.
Keytruda and other antibody therapies place Merck in monoclonal antibody therapeutics.
|
$215.90B |
$85.99
-0.34%
|
|
AMGN
Amgen Inc.
Amgen's portfolio includes monoclonal antibody therapeutics such as Repatha and tezepelumab (TEZSPIRE).
|
$160.47B |
$298.45
+2.21%
|
|
GILD
Gilead Sciences, Inc.
Trodelvy’s antibody component and other cancer therapies align with Monoclonal Antibody Therapeutics.
|
$149.01B |
$119.77
+1.12%
|
|
PFE
Pfizer Inc.
Monoclonal antibody therapeutics represent a major therapeutic modality in Pfizer's portfolio and oncology pipeline.
|
$140.14B |
$24.66
+1.50%
|
|
BMY
Bristol-Myers Squibb Company
Opdivo is a monoclonal antibody immuno-oncology therapy, a core direct product in BMY's Growth Portfolio.
|
$93.77B |
$46.11
+1.07%
|
|
REGN
Regeneron Pharmaceuticals, Inc.
Regeneron’s core business centers on monoclonal antibody therapeutics (e.g., Dupixent, Libtayo).
|
$69.08B |
$651.52
-0.39%
|
|
ZTS
Zoetis Inc.
Zoetis employs monoclonal antibodies for OA pain and dermatology therapies (e.g., Librela, Solensia, Cytopoint), defining a core Monoclonal Antibody Therapeutics product line.
|
$64.15B |
$144.07
+0.33%
|
|
ARGX
argenx SE
argenx's core offerings are monoclonal antibody therapeutics, including VYVGART.
|
$48.94B |
$818.45
-0.23%
|
|
TAK
Takeda Pharmaceutical Company Limited
Entrvyo/vedolizumab and other monoclonal antibody therapies place Takeda in Monoclonal Antibody Therapeutics.
|
$42.61B |
$13.44
+1.59%
|
|
ONC
BeOne Medicines Ltd.
TEVIMBRA is a monoclonal antibody therapy, placing the company in monoclonal antibody therapeutics.
|
$33.55B |
$310.56
+0.76%
|
|
BNTX
BioNTech SE
The company develops monoclonal antibody therapeutics (including bispecifics) for cancer, a core product area.
|
$24.91B |
$103.92
-0.72%
|
|
BIIB
Biogen Inc.
Biogen's portfolio includes monoclonal antibody therapeutics (e.g., LEQEMBI) as a core modality.
|
$22.62B |
$154.27
+3.11%
|
|
GMAB
Genmab A/S
Genmab develops and commercializes monoclonal antibody therapeutics (e.g., antibody-based oncology medicines).
|
$18.93B |
$28.60
-0.24%
|
|
INCY
Incyte Corporation
Monoclonal Antibody Therapeutics is a direct product modality for Monjuvi (tafasitamab) and similar antibody-based cancer therapies.
|
$18.25B |
$93.49
+0.97%
|
|
SMMT
Summit Therapeutics Inc.
Ivonescimab is an antibody-based therapeutic, aligning with Monoclonal Antibody Therapeutics as a core modality.
|
$14.05B |
$18.91
+1.45%
|
|
ROIV
Roivant Sciences Ltd.
Immunovant's FcRn-targeting therapies (e.g., IMVT-1402, batoclimab) are monoclonal antibody therapeutics.
|
$13.59B |
$19.98
+2.07%
|
|
RDY
Dr. Reddy's Laboratories Limited
Monoclonal antibody therapeutics emphasis via biosimilar strategies (e.g., abatacept, rituximab, pembrolizumab collaboration).
|
$11.09B |
$13.30
-1.12%
|
|
ELAN
Elanco Animal Health Incorporated
Monoclonal Antibody Therapeutics platform (CPMA and IL‑31 related programs) constitutes a key technology and product approach.
|
$11.00B |
$22.14
-1.91%
|
|
JAZZ
Jazz Pharmaceuticals plc
Zanidatamab is a monoclonal antibody therapeutic, aligning with Monoclonal Antibody Therapeutics.
|
$8.48B |
$137.62
+0.97%
|
|
RNA
Avidity Biosciences, Inc.
Monoclonal Antibody Therapeutics: uses antibody component for targeting in the AOC platform.
|
$8.42B |
$69.83
+0.20%
|
|
MRUS
Merus N.V.
Core product category: monoclonal antibody therapeutics used in cancer indications.
|
$6.57B |
$94.86
-0.21%
|
|
TGTX
TG Therapeutics, Inc.
BRIUMVI is TG Therapeutics' flagship monoclonal antibody therapeutic (anti-CD20) for relapsing MS, the core product driving revenue and growth.
|
$5.52B |
$34.78
+2.23%
|
|
IMVT
Immunovant, Inc.
IMVT-1402 and batoclimab are monoclonal antibodies targeting FcRn, aligning with monoclonal antibody therapeutics.
|
$4.22B |
$24.69
-0.52%
|
|
APGE
Apogee Therapeutics, Inc.
Directly develops and manufactures monoclonal antibody therapeutics (APG777, APG808, APG990).
|
$3.37B |
$56.55
+0.91%
|
|
CNTA
Centessa Pharmaceuticals plc
LockBody is an antibody-based platform; its advances map to 'Monoclonal Antibody Therapeutics'.
|
$3.33B |
$24.89
+2.32%
|
|
RARE
Ultragenyx Pharmaceutical Inc.
UX143 is a monoclonal antibody; Ultragenyx' portfolio includes monoclonal antibody therapeutics (Crysvita, Evkeeza, UX143).
|
$3.27B |
$34.58
-1.68%
|
|
ZLAB
Zai Lab Limited
Significant monoclonal antibody therapeutics activity across oncology/immunology assets.
|
$2.83B |
$26.12
+2.37%
|
|
SRRK
Scholar Rock Holding Corporation
Directly develops and markets monoclonal antibody therapeutics (apitegromab, SRK-439, SRK-181) across SMA, obesity/metabolic, and oncology.
|
$2.81B |
$29.68
+1.04%
|
|
KNSA
Kiniksa Pharmaceuticals, Ltd.
KPL-387 is a monoclonal antibody targeting IL-1R1, placing the pipeline in monoclonal antibody therapeutics.
|
$2.74B |
$36.98
-0.83%
|
|
ADPT
Adaptive Biotechnologies Corporation
Monoclonal Antibody Therapeutics tag aligns with autoreactive TCR targeting and antibody programs.
|
$2.64B |
$17.36
+2.69%
|
|
BEAM
Beam Therapeutics Inc.
BEAM-103 involves an anti-CD117 monoclonal antibody; includes Monoclonal Antibody Therapeutics as part of its conditioning strategy.
|
$2.51B |
$25.01
+5.08%
|
|
RCUS
Arcus Biosciences, Inc.
Domvanalimab is a monoclonal antibody therapeutic, placing Arcus in the Monoclonal Antibody Therapeutics category.
|
$2.10B |
$19.72
-2.33%
|
|
VRDN
Viridian Therapeutics, Inc.
Lead programs Veligrotug and VRDN-003 are monoclonal antibodies targeting IGF-1R, i.e., Monoclonal Antibody Therapeutics.
|
$1.93B |
$23.64
-0.11%
|
|
VERA
Vera Therapeutics, Inc.
Atacicept is a biologic therapeutic (dual BAFF/APRIL inhibitor) with a monoclonal antibody–like profile, placing Vera's lead program under Monoclonal Antibody Therapeutics.
|
$1.82B |
$28.44
-4.15%
|
|
CLDX
Celldex Therapeutics, Inc.
Barzolvolimab is a therapeutic monoclonal antibody, placing Celldex in Monoclonal Antibody Therapeutics.
|
$1.77B |
$26.70
+2.69%
|
|
BHVN
Biohaven Ltd.
BHVN's Trop2 ADC program aligns with Monoclonal Antibody Therapeutics as a core oncology modality.
|
$1.76B |
$17.20
-1.06%
|
|
OGN
Organon & Co.
Monoclonal antibody therapeutics including Emgality marketed within Organon's portfolio.
|
$1.75B |
$6.75
+2.66%
|
|
JANX
Janux Therapeutics, Inc.
Therapies revolve around monoclonal antibody-based modalities (including bispecific antibodies).
|
$1.70B |
$28.70
+0.67%
|
|
ABCL
AbCellera Biologics Inc.
Company is developing monoclonal antibody therapeutics through wholly-owned programs ABCL635 and ABCL575.
|
$1.66B |
$5.54
+3.36%
|
|
SYRE
Spyre Therapeutics, Inc.
Spyre's pipeline comprises engineered monoclonal antibodies (SPY001/SPY002/SPY003) targeting α4β7, TL1A, and IL-23 for IBD and RA.
|
$1.48B |
$24.47
+0.87%
|
|
IMNM
Immunome, Inc.
Antibody-based therapeutics component of ADCs justifies Monoclonal Antibody Therapeutics tagging.
|
$1.40B |
$16.08
+0.63%
|
|
UPB
Upstream Bio, Inc.
Verekitug is a monoclonal antibody therapeutic targeting the TSLP receptor, directly aligning with Monoclonal Antibody Therapeutics.
|
$1.39B |
$25.86
+0.35%
|
|
ZYME
Zymeworks Inc.
Company develops monoclonal antibody therapeutics as a core modality.
|
$1.33B |
$19.07
-0.26%
|
|
ZBIO
Zenas BioPharma, Inc.
Obexelimab is a monoclonal antibody therapeutic developed by the company.
|
$1.31B |
$31.25
+4.60%
|
|
TRML
Tourmaline Bio, Inc.
Pacibekitug is a monoclonal antibody therapeutic targeting IL-6, fitting Monoclonal Antibody Therapeutics.
|
$1.23B |
$47.98
+0.01%
|
|
INBX
Inhibrx Biosciences, Inc.
Monoclonal antibody therapeutics addressing cancer targets with multivalent formats.
|
$1.18B |
$81.68
+4.04%
|
|
SNDX
Syndax Pharmaceuticals, Inc.
Niktimvo axatilimab-csfr is a monoclonal antibody therapy, fitting Monoclonal Antibody Therapeutics.
|
$1.18B |
$13.71
+2.35%
|
|
DNTH
Dianthus Therapeutics, Inc.
Lead product is a monoclonal antibody therapeutic targeting active C1s, a core product category.
|
$1.12B |
$34.96
+3.62%
|
|
OPK
OPKO Health, Inc.
ModeX antibody therapies fall under monoclonal antibody therapeutics.
|
$1.08B |
$1.34
-7.88%
|
|
ANAB
AnaptysBio, Inc.
Lead programs are monoclonal antibody therapeutics (antibodies such as rosnilimab, ANB033, ANB101).
|
$1.07B |
$36.58
+0.29%
|
|
XNCR
Xencor, Inc.
Core output includes engineered monoclonal antibody therapeutics via the XmAb platform.
|
$1.05B |
$14.70
+4.00%
|
|
NRIX
Nurix Therapeutics, Inc.
The narrative references antibody therapies in addition to small molecule degraders, aligning with Monoclonal Antibody Therapeutics.
|
$989.25M |
$12.95
+1.33%
|
|
KOD
Kodiak Sciences Inc.
Lead assets are monoclonal antibody therapeutics designed for retinal disease, aligning with Monoclonal Antibody Therapeutics.
|
$956.34M |
$18.18
-13.66%
|
|
BCAX
Bicara Therapeutics Inc. Common Stock
Lead product is a monoclonal antibody–type therapeutic, aligning with Monoclonal Antibody Therapeutics.
|
$886.21M |
$16.24
-1.34%
|
|
VIR
Vir Biotechnology, Inc.
VIR's antibody-based approaches include monoclonal antibody therapeutics targeting cancer antigens.
|
$823.90M |
$5.95
+0.34%
|
|
OCS
Oculis Holding AG
OCS-02 Licaminlimab is an antibody-based therapeutic (monoclonal antibody therapeutics).
|
$808.70M |
$19.22
-4.33%
|
|
NKTR
Nektar Therapeutics
NKTR-0165 is a monoclonal antibody therapeutic (TNFR2 agonist), aligning with Monoclonal Antibody Therapeutics.
|
$805.58M |
$64.90
+3.34%
|
|
RZLT
Rezolute, Inc.
Ersodetug is a human monoclonal antibody designed to treat HI by modulating insulin signaling, representing a monoclonal antibody therapeutic product.
|
$797.04M |
$9.32
-5.04%
|
|
ATXS
Astria Therapeutics, Inc.
Astria Therapeutics develops monoclonal antibody therapeutics (navenibart and STAR-0310).
|
$712.76M |
$12.63
+0.96%
|
|
ERAS
Erasca, Inc.
ERAS-12 is an EGFR biparatopic antibody, constituting Monoclonal Antibody Therapeutics.
|
$685.56M |
$2.42
-1.63%
|
|
EBS
Emergent BioSolutions Inc.
Ebanga is a monoclonal antibody therapeutic developed by Emergent for Ebola; this aligns with the Monoclonal Antibody Therapeutics investable theme.
|
$665.82M |
$12.48
-2.80%
|
|
AVBP
ArriVent BioPharma, Inc. Common Stock
ADC programs involve monoclonal antibody components; ARR-217 implies monoclonal antibody therapeutics as part of the ADC strategy.
|
$640.80M |
$18.73
+1.38%
|
|
SIGA
SIGA Technologies, Inc.
SIGA's pipeline includes fully human monoclonal antibodies licensed from Vanderbilt, aligning with Monoclonal Antibody Therapeutics.
|
$591.53M |
$8.27
-0.48%
|
|
PRTA
Prothena Corporation plc
Prothena's core assets are monoclonal antibody therapeutics (PRX012, PRX019, PRX123, etc.) across neurodegenerative diseases, including Alzheimer's and other indications.
|
$578.64M |
$10.73
+2.43%
|
|
ABSI
Absci Corporation
Internal programs ABS-101/ABS-201/ABS-301/ABS-501 are antibody-based therapeutics targeting oncology and immunology, aligning with Monoclonal Antibody Therapeutics.
|
$545.95M |
$4.29
+4.77%
|
|
IMAB
I-Mab
I-Mab develops monoclonal antibody therapeutics, including uliledlimab (CD73 antibody) and other antibody-based assets.
|
$533.68M |
$4.64
|
|
MNPR
Monopar Therapeutics Inc.
MNPR-101 is a humanized monoclonal antibody targeting uPAR, fitting Monoclonal Antibody Therapeutics.
|
$526.89M |
$88.06
+2.79%
|
|
CMPX
Compass Therapeutics, Inc.
Company develops Monoclonal Antibody Therapeutics for oncology applications.
|
$517.18M |
$3.73
+0.40%
|
|
CGEM
Cullinan Therapeutics, Inc.
Antibody-based therapeutics (monoclonal antibodies) are a direct product modality for CLN-978 and velinotamig.
|
$511.07M |
$8.66
+14.62%
|
|
RAPT
RAPT Therapeutics, Inc.
RPT904 is a monoclonal antibody therapeutic, fitting Monoclonal Antibody Therapeutics.
|
$499.56M |
$30.17
+1.58%
|
|
PRTC
PureTech Health plc
LYT-200 is a monoclonal antibody therapeutic, a core biologics modality.
|
$458.47M |
$17.68
+3.97%
|
|
ADCT
ADC Therapeutics S.A.
ZYNLONTA uses a monoclonal antibody as its targeting moiety, fitting Monoclonal Antibody Therapeutics.
|
$442.34M |
$4.45
-3.89%
|
|
OMER
Omeros Corporation
Narsoplimab and zaltenibart OMS906 are monoclonal antibody therapeutics, a core product class for Omeros.
|
$429.48M |
$7.32
-2.66%
|
|
YMAB
Y-mAbs Therapeutics, Inc.
DANYELZA (naxitamab-gqgk) is a monoclonal antibody therapeutic.
|
$389.89M |
$8.61
|
|
ITOS
iTeos Therapeutics, Inc.
Belrestotug is a monoclonal antibody targeting TIGIT, indicating direct production of monoclonal antibody therapeutics.
|
$388.48M |
$10.15
|
|
VIGL
Vigil Neuroscience, Inc.
Direct product: Vigil's lead program iluzanebart is a fully human monoclonal antibody TREM2 agonist, categorizing under Monoclonal Antibody Therapeutics.
|
$375.71M |
$8.05
|
|
ANNX
Annexon, Inc.
Annexon's lead programs are monoclonal antibody therapeutics (ANX005, ANX009) targeting C1q.
|
$346.70M |
$3.16
+7.85%
|
|
ACIU
AC Immune S.A.
Monoclonal Antibody Therapeutics – AC Immune develops conformation-specific monoclonal antibodies via SupraAntigen platforms.
|
$337.46M |
$3.38
|
|
MREO
Mereo BioPharma Group plc
Setrusumab is a monoclonal antibody therapeutic, aligning with Monoclonal Antibody Therapeutics.
|
$302.10M |
$1.90
+0.26%
|
|
CTMX
CytomX Therapeutics, Inc.
PROBODY therapeutics are monoclonal antibody–based biologics, aligning with Monoclonal Antibody Therapeutics.
|
$287.82M |
$3.57
+7.21%
|
|
IMMP
Immutep Limited
IMP761 is described as a LAG-3 agonist antibody, aligning with Monoclonal Antibody Therapeutics.
|
$275.11M |
$1.88
-2.08%
|
|
ACRS
Aclaris Therapeutics, Inc.
Bosakitug and other assets are monoclonal antibody therapeutics, matching Monoclonal Antibody Therapeutics.
|
$272.87M |
$2.52
+1.20%
|
|
ELDN
Eledon Pharmaceuticals, Inc.
Tegoprubart is an IgG1 monoclonal antibody therapeutic targeting CD40L.
|
$258.69M |
$4.32
-0.69%
|
|
ALMS
Alumis Inc. Common Stock
Lonigutamab is a monoclonal antibody therapy, a direct product in the biopharma pipeline.
|
$258.43M |
$4.75
+1.93%
|
|
VYGR
Voyager Therapeutics, Inc.
VY7523 is a monoclonal antibody targeting tau, category: Monoclonal Antibody Therapeutics.
|
$258.42M |
$4.67
+3.32%
|
|
VNDA
Vanda Pharmaceuticals Inc.
Imsidolimab is a monoclonal antibody therapeutic targeting IL-36R for generalized pustular psoriasis.
|
$257.04M |
$4.33
+0.35%
|
|
ZURA
Zura Bio Limited
Crebankitug and torudokimab are monoclonal antibodies in Zura Bio's pipeline (Monoclonal Antibody Therapeutics).
|
$237.60M |
$3.84
+2.40%
|
|
SLRN
Acelyrin, Inc.
Lonigutamab is a monoclonal antibody therapeutic (IGF-1R) being developed as a treatment for TED, aligning with Monoclonal Antibody Therapeutics.
|
$228.61M |
$2.27
|
|
PYXS
Pyxis Oncology, Inc.
ADC therapy leveraging a monoclonal antibody to deliver a cytotoxic payload.
|
$220.53M |
$3.57
+4.39%
|
|
IVVD
Invivyd, Inc.
Invivyd's PEMGARDA and pipeline candidate VYD2311 are monoclonal antibody therapeutics targeting evolving viral threats, making Monoclonal Antibody Therapeutics the core product category.
|
$211.13M |
$1.76
-5.61%
|
|
TLSA
Tiziana Life Sciences Ltd
TLSA's lead product Foralumab is a fully human monoclonal antibody therapeutic, placing the company in Monoclonal Antibody Therapeutics.
|
$197.93M |
$1.90
+3.26%
|
|
AVTX
Avalo Therapeutics, Inc.
AVTX-9.00 is an anti-IL-1β monoclonal antibody, directly fitting Monoclonal Antibody Therapeutics.
|
$195.22M |
$17.88
-0.86%
|
|
CHRS
Coherus Oncology, Inc.
LOQTORZI is a differentiated PD-1 monoclonal antibody and commercial oncology product, aligning with Monoclonal Antibody Therapeutics.
|
$194.77M |
$1.67
-1.76%
|
|
IPHA
Innate Pharma S.A.
Lacutamab and monalizumab are monoclonal antibodies, aligning with Monoclonal Antibody Therapeutics.
|
$159.51M |
$1.97
-1.26%
|
|
CGEN
Compugen Ltd.
COM701 and GS-0321 are monoclonal antibody therapeutics in development, aligning with Monoclonal Antibody Therapeutics.
|
$158.48M |
$1.77
+7.58%
|
|
THTX
Theratechnologies Inc.
Trogarzo is a monoclonal antibody therapy for multidrug-resistant HIV, a direct product offering.
|
$155.87M |
$3.39
|
Showing page 1 of 2 (152 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
